Pasireotide in Prevention of GI Toxicity | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02215070

Pasireotide in Prevention of GI Toxicity
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The purpose of this study is to evaluate if the drug, Pasireotide, is safe and effective in reducing the gastrointestinal side effects of the drugs received to prepare for allogeneic stem cell transplant. The study will also evaluate if Pasireotide is effective in reducing acute and chronic Graft-versus-Host-Disease (GvHD) after transplant.

Status: 
Recruiting
Study Date: 
Sun, 02/01/2015 to Tue, 01/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Pasireotide + Chemo Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Chemotherapy (Busulfan) will be given 4 days before stem cell transplant. Drug: Pasireotide + Total Body Irradiation Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Total Body Irradiation (TBI) will be given 4 days before stem cell transplant.